Incidence and pre/post-treatment risk factors of glaucoma in Vogt-Koyanagi-Harada disease

Int Ophthalmol. 2023 Aug;43(8):2857-2866. doi: 10.1007/s10792-023-02688-0. Epub 2023 Mar 17.

Abstract

Purpose: To investigate the incidence and pre/post-treatment risk factors of glaucoma in patients with Vogt-Koyanagi-Harada (VKH) disease.

Methods: Data regarding secondary glaucoma were collected from the medical records of patients with VKH disease who were followed up at the uveitis service at Hiroshima University for more than 6 months. We examined the incidence of glaucoma and pre/post-treatment risk factors for glaucoma in patients with VKH disease.

Results: Forty-nine patients with VKH disease were included in this study (31 women and 18 men). The mean age at onset was 50.4 ± 15.4 years and the mean length of follow-up was 40.7 ± 25.5 months. The most common initial treatment was pulse intravenous corticosteroid therapy (89.8%). Fifteen patients developed secondary glaucoma during follow-up. The median time of glaucoma onset from VKH development was 4.5 months (range 0-44 months). Disc swelling type as a pre-treatment factor (p = 0.089, hazard ratio = 7.268), worse final best corrected visual acuity (p = 0.099, odds ratio = 1.545), and cataract progression (p = 0.076, odds ratio = 7.886) as post-treatment factors showed trends for glaucoma development. The patients who progressed to the chronic recurrent stage had more complications including glaucoma.

Conclusion: Secondary glaucoma occurred in more than 30% of patients with VKH disease. The factors that showed a trend toward glaucoma development may reflect an association with delayed treatment initiation and prolonged ocular inflammation.

Keywords: Complications; Glaucoma; Incidence; Japan; Uveitis; Vogt-Koyanagi-Harada Disease.

MeSH terms

  • Female
  • Glaucoma* / diagnosis
  • Glaucoma* / epidemiology
  • Glaucoma* / etiology
  • Humans
  • Incidence
  • Male
  • Retrospective Studies
  • Risk Factors
  • Uveomeningoencephalitic Syndrome* / complications
  • Uveomeningoencephalitic Syndrome* / diagnosis
  • Uveomeningoencephalitic Syndrome* / drug therapy
  • Visual Acuity